CAMP4 Therapeutics (NASDAQ:CAMP) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded CAMP4 Therapeutics from “hold” to “sell.” Despite the downgrade, the broader analyst consensus remains “Moderate Buy,” with seven Buy ratings, one Hold, one Sell, and a $10.86 average price target.
• CAMP shares opened at $3.77, well below the 52-week high of $7.75. The company recently reported an earnings-per-share loss of $0.58, missing expectations by $0.34, alongside $1.78 million in quarterly revenue.
• Insider activity was mixed: insiders bought 46,031 shares worth $99,051 over the past 90 days but sold 593,613 shares valued at $2.5 million. CAMP4 is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday, Wall Street Zen reports.

CAMP has been the subject of a number of other research reports. Cantor Fitzgerald restated an "overweight" rating on shares of CAMP4 Therapeutics in a research report on Tuesday, September 29th. Weiss Ratings cut shares of CAMP4 Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, October 2nd. Chardan Capital decreased their price target on shares of CAMP4 Therapeutics from $6.50 to $6.00 and set a "buy" rating on the stock in a research note on Tuesday, September 29th. Oppenheimer started coverage on shares of CAMP4 Therapeutics in a report on Monday, October 5th. They issued an "outperform" rating and a $15.00 price objective for the company. Finally, UBS Group set a $15.00 price objective on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, CAMP4 Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $10.86.

CAMP4 Therapeutics Price Performance

Shares of CAMP4 Therapeutics stock opened at $3.77 on Friday. CAMP4 Therapeutics has a 1 year low of $2.86 and a 1 year high of $7.75. The firm has a market cap of $236.57 million, a PE ratio of -1.63 and a beta of 0.27. The company has a 50 day simple moving average of $4.20 and a two-hundred day simple moving average of $4.21.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The company had revenue of $1.78 million for the quarter. As a group, research analysts anticipate that CAMP4 Therapeutics will post -0.66 earnings per share for the current year.

Insider Transactions at CAMP4 Therapeutics

In related news, Director Richard Young bought 16,378 shares of the company's stock in a transaction dated Monday, August 3rd. The stock was purchased at an average cost of $1.65 per share, with a total value of $27,023.70. Following the transaction, the director owned 186,388 shares in the company, valued at approximately $307,540.20. This trade represents a 9.63% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kelly Gold purchased 10,000 shares of CAMP4 Therapeutics stock in a transaction that occurred on Monday, August 31st. The shares were bought at an average price of $3.96 per share, for a total transaction of $39,600.00. Following the transaction, the chief financial officer directly owned 10,000 shares of the company's stock, valued at $39,600. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders purchased 46,031 shares of company stock valued at $99,051 and sold 593,613 shares valued at $2,504,037. Corporate insiders own 21.69% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Bank of America Corp DE bought a new position in CAMP4 Therapeutics in the 2nd quarter valued at approximately $78,000. Deutsche Bank AG bought a new stake in CAMP4 Therapeutics in the 2nd quarter worth approximately $138,000. Bank of New York Mellon Corp bought a new position in CAMP4 Therapeutics in the second quarter valued at about $365,000. EcoR1 Capital LLC bought a new position in shares of CAMP4 Therapeutics in the 4th quarter worth approximately $1,992,000. Finally, SummitTX Capital L.P. purchased a new position in shares of CAMP4 Therapeutics in the first quarter worth approximately $1,497,000.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company's approach is designed to increase expression of a patient's existing genes rather than replace or edit them.

CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.